Alkem Labs enters into licensing agreement with Sonnet BioTherapeutics for its diabetic peripheral neuropathy drug in India
- Posted on October 11, 2024
- By Financial Express
- 1 Views
Alkem Labs enters into licensing agreement with Sonnet BioTherapeutics for its diabetic peripheral neuropathy drug in India
India is grappling with a substantial burden of diabetes-related complications with diabetic peripheral neuropathy being a major one.
